This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $300 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoLive In-Person Event: December 4 - 8, 2022

Katherine Harris, PhD
Vice President, Discovery at Amgen


Katherine Harris is Vice President of Discovery at Amgen where she leads Oncology Research at the Amgen Newark site, pursuing novel multi-specific molecules to modulate the anti-tumor immune response.  Previously she served as Vice President of Discovery at Teneobio where she led the Discovery and Lead Optimization team in the development of multi-specific therapeutic antibodies. She joined Teneobio when the company started lab operations in 2015, playing a key role in the strategic direction of the company as well as building and managing a high-throughput antibody discovery platform.  Prior to Teneobio, she worked at Active Motif and SwitchGear Genomics where she focused her efforts on developing a functional genomics platform for small molecule screening.  Dr. Harris holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.

Agenda Sessions

  • Co-Chairs’ Remarks